1 / 13

RENAL FAILURE

RENAL FAILURE. DR. HANIN. Goals of therapy. The aim of medical care is to: Delaying or halting the progression of CKD Treating the pathologic manifestations of CKD Timely planning for long-term renal replacement therapy. 1. Delaying or Halting Progression of Chronic Kidney Disease.

knox-scott
Download Presentation

RENAL FAILURE

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. RENAL FAILURE DR. HANIN

  2. Goals of therapy • The aim of medical care is to: • Delaying or halting the progression of CKD • Treating the pathologic manifestations of CKD • Timely planning for long-term renal replacement therapy

  3. 1. Delaying or Halting Progression of Chronic Kidney Disease • Treatment of the underlying condition if possible • Aggressive blood pressure control with ACE inhibitors • Treatment of hyperlipidemia with Statins • Aggressive glycemic control target HbA1C < 7% • Avoidance of nephrotoxins • Use of ACEIs /ARBs in patients with diabetic kidney disease and proteinuria • Use of ACEIs or angiotensin-receptor blockers (ARBs) in patients with proteinuria

  4. 2. Treating Pathologic Manifestations of Chronic Kidney Disease • Anemia: • When the HB < 10 g/dL, treat with Erythropoietin • Before starting erythropoietin, check iron stores.

  5. Management of mineral and bone disorder • Lowering high serum phosphorus levels: Treat with dietary phosphate binders (calcium acetate, sevelamer carbonate) and dietary phosphate restriction. • Maintaining serum calcium levels: Treat with calcium supplements with or without calcitriol

  6. Lowering serum parathyroid hormone levels: Treat with calcitriol, vitamin D analogues, or calcimimetics (mimics calcium at the parathyroid hormone (PTH) receptor and reduces PTH levels. Cinacalcet is the only drug in this class) • Providing osteoporosis prophylaxis

  7. 3. Diet • Protein restriction; 0.8g/kg body weight • Salt restriction and water restriction: salt 2 g/d, water 1-1.5 L/day • Phosphorus restriction 600-800 mg/day • Potassium restriction 40-70 mEq/day

  8. 4. Management of hyperkalemia • Continuous monitoring of ECG • Restrict dietary potassium • Discontinue potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers . • Sodium polystyrene sulfonate (SPS) enhance GI excretion. SPS can be administered orally or rectally. It is not used for emergency treatment. • Calcium gluconate 10% to ameliorate cardiac toxicity if present. • Drugs that lowers serum potassium: Insulin + 50% dextrose, Nebulized Salbutamol, Loop diuretic • Emergency dialysis

  9. 5. Others • Volume overload: Treat with loop diuretics or ultrafiltration • Metabolic acidosis: Treat with oral alkali supplementation • Uremic manifestations: Treat with long-term renal replacement therapy • Cardiovascular complications: Treat as appropriate • Growth failure in children: Treat with growth hormone

  10. 3. Renal Replacement Therapy • long-term renal replacement therapy include; • Hemodialysis • Peritoneal dialysis • Renal transplantation

  11. Indications for renal replacement therapy in patients with chronic kidney disease (CKD) • Severe metabolic acidosis • Hyperkalemia • Pericarditis • Encephalopathy • Intractable volume overload • Failure to thrive and malnutrition • Peripheral neuropathy • Intractable gastrointestinal symptoms • In asymptomatic adult patients, a glomerular filtration rate (GFR) of 5-9 mL/min/1.73 m², irrespective of the cause of the CKD or the presence of absence of other comorbidities

  12. Considerations • Early patient education regarding natural disease progression, different dialytic modalities, renal transplantation. • Timely placement of permanent vascular access (arrange for surgical creation of primary arteriovenous fistula, if possible, and preferably at least 6 months in advance of the anticipated date of dialysis for patients in whom transplantation is not imminent) • Timely elective peritoneal dialysis catheter insertion • Timely referral for renal transplantation

  13. GOOD LUCK

More Related